Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD + THC added to standard chemoradiotherapy and adjuvant temozolomide versus placebo in newly diagnosed glioblastoma
MOH_2019-04-01_006055Phase 2Completed
- Sponsor
- BOL Pharma
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cannabidiol and dronabinol in glioblastoma (GBM) (2 arms), sponsored by BOL Pharma. Started May 2018; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2019-04-01_006055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-01_006055.